Current Therapeutic Approaches in Metastatic and Recurrent Ewing Sarcoma

Ewing sarcoma (ES) is the second most common type of primary bone malignancy in children and young adults. Survival rates for localized ES have improved to upwards of 70% with aggressive chemotherapy and local control. On the other hand, there has been little improvement in survival rates for patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Michael, Lucas, Kenneth
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2995926/
https://www.ncbi.nlm.nih.gov/pubmed/21151650
http://dx.doi.org/10.1155/2011/863210
_version_ 1782193128789245952
author Huang, Michael
Lucas, Kenneth
author_facet Huang, Michael
Lucas, Kenneth
author_sort Huang, Michael
collection PubMed
description Ewing sarcoma (ES) is the second most common type of primary bone malignancy in children and young adults. Survival rates for localized ES have improved to upwards of 70% with aggressive chemotherapy and local control. On the other hand, there has been little improvement in survival rates for patients with metastatic or recurrent ES. Herein we review the different current therapeutic approaches available, including the different upfront and salvage chemotherapy regimens, the role for stem cell transplantation, and potential use of immunotherapy.
format Text
id pubmed-2995926
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-29959262010-12-13 Current Therapeutic Approaches in Metastatic and Recurrent Ewing Sarcoma Huang, Michael Lucas, Kenneth Sarcoma Review Article Ewing sarcoma (ES) is the second most common type of primary bone malignancy in children and young adults. Survival rates for localized ES have improved to upwards of 70% with aggressive chemotherapy and local control. On the other hand, there has been little improvement in survival rates for patients with metastatic or recurrent ES. Herein we review the different current therapeutic approaches available, including the different upfront and salvage chemotherapy regimens, the role for stem cell transplantation, and potential use of immunotherapy. Hindawi Publishing Corporation 2011 2010-12-01 /pmc/articles/PMC2995926/ /pubmed/21151650 http://dx.doi.org/10.1155/2011/863210 Text en Copyright © 2011 M. Huang and K. Lucas. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Huang, Michael
Lucas, Kenneth
Current Therapeutic Approaches in Metastatic and Recurrent Ewing Sarcoma
title Current Therapeutic Approaches in Metastatic and Recurrent Ewing Sarcoma
title_full Current Therapeutic Approaches in Metastatic and Recurrent Ewing Sarcoma
title_fullStr Current Therapeutic Approaches in Metastatic and Recurrent Ewing Sarcoma
title_full_unstemmed Current Therapeutic Approaches in Metastatic and Recurrent Ewing Sarcoma
title_short Current Therapeutic Approaches in Metastatic and Recurrent Ewing Sarcoma
title_sort current therapeutic approaches in metastatic and recurrent ewing sarcoma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2995926/
https://www.ncbi.nlm.nih.gov/pubmed/21151650
http://dx.doi.org/10.1155/2011/863210
work_keys_str_mv AT huangmichael currenttherapeuticapproachesinmetastaticandrecurrentewingsarcoma
AT lucaskenneth currenttherapeuticapproachesinmetastaticandrecurrentewingsarcoma

Ejemplares similares